Goal 4: Develop Workforce and Resources

Submitted by (@mallampallirk)

Training in Small Molecule Discovery and Development

The current generation of heart,lung, and blood investigators are not equipped with competitive training needed to approach, design, and test appropriately small molecule therapeutics that may move through the FDA pipeline. Appropriate in silico ligan or structure based design, HTS, design of Pd/Pk models, "go-no-go" branchpoints in drug development, screening approaches, and drug target validation are issues that are ...more »

Voting

3 net votes
10 up votes
7 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@wjones7)

Open up NCATS

The NCATS program for drug repurposing is currently only open to drugs submitted by industry (read, big Pharma). We have had the experience of working to repurpose a generic drug not on their list, and despite great Preliminary data, we could not. This program is a great idea, but needs to be opened to any company and any drug for which solid data backing efficacy and market can be applied. Why do we only want to enhance ...more »

Voting

-5 net votes
5 up votes
10 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@nhlbiforumadministrator1)

A Program of Research in the Prevention of Chronic Heart Failure

There is a need to address chronic heart failure (HF) through improved identification of patients at risk for HF and of patients with pathological ventricular remodeling who have minimal evidence of clinical HF, and more focused and individualized pharmacologic and lifestyle treatments and monitoring of patients with HF risk. Approaches would include big data collection, omics, statistical modeling, and focused clinical ...more »

Voting

17 net votes
28 up votes
11 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@wheeze)

Drug Desensitization Protocols

As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan: Given that increasing number of patients allergic to their best medications are treated with desensitization, which allows improved quality of life and prolongs their lives, ¬†what ¬†personalized, effective and safe protocols ...more »

Voting

-9 net votes
4 up votes
13 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@mtothbsf)

Substituting scientific-medical insight before profit in drug development

Since the Pure Food and Drug Act of 1906 and the rise of the FDA, the US federal government has directly inserted itself into medical research, primarily from a business perspective. The Orphan Drug Act of 1983 monetarily incentivized the process for rare diseases, but for ultra-rare diseases of < 1,000 patients, it does not work. Successful drugs for rare diseases have enormous price tags to compensate their development ...more »

Voting

6 net votes
11 up votes
5 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@wheeze)

Genetic and Molecular Tools for Drug Allergy - Hypersensitivity

As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan: Given that more patients are treated with newer and better targeted medications including chemotherapy, monoclonal antibodies, small molecules and others that have increased the number of hypersensitivity reactions, which ...more »

Voting

-4 net votes
10 up votes
14 down votes
Active